NCT00192192已完成3 期
A Randomized, Double-Blind, Placebo-Controlled Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold Adapted (CAIV-T) in Healthy Adults Aged 18 to 64 Years
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- Assays on blood, serum, nasal wash samples and cells obtained from healthy adult subjects
研究概览
简要总结
To perform a variety of assays on blood, serum, nasal wash samples and cells obtained from healthy adult subjects for the purposes of developing assays for application in the further investigation of immune responses generated by influenza virus vaccine, trivalent, types A and B, live, cold-adapted (liquid CAIV-T; Wyeth Lederle Vaccines, Marietta, PA).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 64 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •who are between 18 to 64 years of age. Subject must be at least 18 years of age and no older than 64 years of age at the time informed consent is obtained;
- •eligible female subjects, who are of childbearing potential, who have a negative urine pregnancy test results prior to study vaccination. Females who are surgically sterile or post-menopausal do not require pregnancy testing.
- •who are determined by medical history, physical examination and clinical judgement to be eligible for this study. Subjects with stable pre-existing disease, defined as disease not requiring change in therapy or hospitalization within 12 weeks before receipt of study vaccination will be eligible.
- •who have provided written informed consent after the nature of the study has been explained;
- •who, will be available for two month duration of the trial (from enrollment to study completion);
- •who can be reached by study staff for the post-vaccination contact [telephone, clinic or home visit]
排除标准
- •who are perceived to be unavailable or difficult to contact for evaluation or study visits during the study period
- •with a known or suspected disease of the immune system or those receiving immunosuppressive therapy, including systemic corticosteroids; or cytotoxic agents;
- •who received any blood products, including immunoglobulin, in the period from six months prior to vaccination through to the conclusion of the study;
- •have an immunosuppressed or an immunocompromised individual living in the same household;
- •with a documented history of hypersensitivity to egg or egg protein or any other component of the study vaccine or placebo;
- •who were administered any live virus vaccine within one month prior to enrollment;
- •for whom there is intent to administer any other investigational vaccine or agent from one month prior to enrollment through to the conclusion of the study;
- •who, received a dose of influenza treatment (commercial or investigational) one month prior to enrollment. The prophylactic use of influenza antivirals is not permitted.
- •who receive any influenza vaccine in the 6 months prior to enrollment, or a non-study influenza vaccine since enrollment;
- •with any medical conditions that in the opinion of the investigator might interfere with interpretation of the study results; Note: A pregnant household member is not considered a contraindication to enrollment.
结局指标
主要结局
Assays on blood, serum, nasal wash samples and cells obtained from healthy adult subjects
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine (CAIV-T) in Healthy ChildrenInfluenzaNCT00192322MedImmune LLC173
已完成
2 期
Phase II Study to Investigate the Kinetics of the Immune Response Generated by Influenza Virus Vaccine.InfluenzaNCT00192309MedImmune LLC31
已完成
3 期
Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine,(CAIV-T)InfluenzaNCT00192231MedImmune LLC120
已完成
2 期
A Phase IIA Study of BMS-512148 to Assess Safety, Exposure, and Biological Effects in Stable Type 2 Diabetic SubjectsDiabetes Mellitus, Type 2NCT00162305AstraZeneca47
已完成
2 期
Study of XL784 in Patients With Albuminuria Due to Diabetic NephropathyAlbuminuriaDiabetic NephropathyNCT00312780Symphony Evolution, Inc.125